SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

CTE Cryosite Limited

Healthcare · Diagnostics & Research · website · 27 employees
$1.15
52wk 0.84 – 1.40
Overall
57.0
Value
35.5
Growth
62.1
Health
54.3
Quality
88.6
Momentum
50.7
Dividend
—
Price
About Cryosite Limited

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell and gene therapies (CGT), cell therapies, mRNA-based medicines, biological samples, and research and development materials requiring high-integrity cold storage. The Cord Blood segment provides storage of cord blood cell and tissue samples for personal or directed therapeutic use by maintaining under validated chain-of-identity controls. It also offers reverse logistics services, secondary packaging, inventory management, and quality transportation and distribution solutions. Cryosite Limited was incorporated in 1999 and is based in South Granville, Australia.

Price analytics

Returns

1 day 0.0%
1 week -2.5%
1 month -8.0%
3 months -8.0%
6 months 5.5%
1 year 33.7%
3 years 76.9%

Risk

Volatility (1y ann.) 42.6%
Beta vs ASX 200 0.47
Sharpe (1y) 0.80
VaR 95% (1-day) -2.8%
Max drawdown (1y) -23.1%
Off 1-year high -11.5%

Technicals

RSI(14) 20 OS
vs 50DMA -5.0%
vs 200DMA 1.0%
Trend Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 35.5
Trailing P/E
35
Forward P/E
—
PEG ratio
59
EV / EBITDA
17
Price / Book
0
Price / Sales
72
Growth 62.1
Revenue growth (1y)
81
Revenue CAGR (3y)
67
EPS growth (1y)
40
EPS CAGR (3y)
59
Financial Health 54.3
Net debt / EBITDA
68
Interest coverage (EBIT/interest)
100
Current ratio
31
Debt / Equity
23
Quality (Profitability & Cash Flow) 88.6
Return on equity
100
Return on assets
87
Operating margin
75
Net margin
89
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 50.7
6-month return vs ASX 200
63
Price vs 200-day average
53
Price vs 50-day average
25
Position in 52-week range
55

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$56.13M
P/E (trailing)
28.75
P/E (forward)
—
EPS (trailing)
0.04
Dividend yield
—
Payout ratio
0.0%
Beta
0.16
EV / EBITDA
17.34
Price / Book
11.62
ROE
61.7%
Operating margin
18.8%
Net margin
13.4%
Total cash
$2.24M
Total debt
$7.72M
Current ratio
1.32
Debt / Equity
1.59
Free cash flow
$166.41M
Avg volume
1,554
Latest annual results (FY ending 30 Jun 2026)
  • Revenue$16.70M
  • Gross profit$10.43M
  • Operating income$3.16M
  • Net income$2.23M
  • Diluted EPS—
  • Free cash flow-$8.05M
  • Net debt$5.47M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4